HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.

Abstract
The low-density lipoprotein cholesterol (LDL-C) lowering efficacy of switching to ezetimibe/simvastatin (EZ/S) 10/20 mg versus doubling the run-in statin dose (to simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg in subjects with cardiovascular disease (CVD) and diabetes was assessed. Endpoints included percentage change in LDL-C and percentage of patients achieving LDL-C <70 mg/dL. Significantly greater reductions in LDL-C occurred when switching to EZ/S versus statin doubling in the overall population and in subjects treated with simvastatin 20 mg or atorvastatin 10 mg (all p < 0.001). The LDL-C reduction was numerically greater when switching to EZ/S versus switching to rosuvastatin (p = 0.060). Significantly more subjects reached LDL-C <70 mg/dL with EZ/S (54.5%) versus statin doubling (27.0%) or rosuvastatin (42.5%) in the overall population (all p < 0.001) and within each stratum (all p < 0.001). Switching to EZ/S provided significantly greater reductions in LDL-C versus statin doubling and significantly greater achievement of LDL-C targets versus statin doubling or switching to rosuvastatin.
AuthorsJeffrey B Rosen, Jose G Jimenez, Valdis Pirags, Hella Vides, Mary E Hanson, Rachid Massaad, Gail McPeters, Philippe Brudi, Joseph Triscari
JournalDiabetes & vascular disease research (Diab Vasc Dis Res) Vol. 10 Issue 3 Pg. 277-86 (May 2013) ISSN: 1752-8984 [Electronic] England
PMID23288881 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Anticholesteremic Agents
  • Azetidines
  • Cholesterol, LDL
  • Drug Combinations
  • Ezetimibe, Simvastatin Drug Combination
  • Fluorobenzenes
  • Heptanoic Acids
  • Pyrimidines
  • Pyrroles
  • Sulfonamides
  • Rosuvastatin Calcium
  • Atorvastatin
  • Simvastatin
Topics
  • Aged
  • Aged, 80 and over
  • Anticholesteremic Agents (administration & dosage, adverse effects, therapeutic use)
  • Atorvastatin
  • Azetidines (adverse effects, therapeutic use)
  • Cardiovascular Diseases (etiology, prevention & control)
  • Cholesterol, LDL (blood)
  • Diabetes Complications (blood, drug therapy, physiopathology)
  • Diabetic Angiopathies (etiology, prevention & control)
  • Double-Blind Method
  • Drug Combinations
  • Drug Monitoring
  • Ezetimibe, Simvastatin Drug Combination
  • Female
  • Fluorobenzenes (adverse effects, therapeutic use)
  • Heptanoic Acids (administration & dosage, adverse effects, therapeutic use)
  • Humans
  • Hypercholesterolemia (blood, complications, drug therapy, physiopathology)
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Pyrimidines (adverse effects, therapeutic use)
  • Pyrroles (administration & dosage, adverse effects, therapeutic use)
  • Rosuvastatin Calcium
  • Severity of Illness Index
  • Simvastatin (administration & dosage, adverse effects, therapeutic use)
  • Sulfonamides (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: